Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit.The new formulation called Penbraya is manufactured by Pfizer and combines the components from two existing meningococcal vaccines, Trumenba the group B vaccine and Nimenrix groups A, C, W-135, and Y conjugate vaccine.
"Today marks an important step forward in the prevention of meningococcal disease in the US," Annaliesa Anderson, PhD, head of vaccine research and development at Pfizer, said in a news release."In a single vaccine, Penbraya has the potential to protect more adolescents and young adults from this severe and unpredictable disease by providing the broadest meningococcal coverage in the fewest shots.
The CDC Advisory Committee on Immunization Practices is meeting on Wednesday to discuss recommendations for the appropriate use of Penbraya in young people.